Search results
Results from the WOW.Com Content Network
Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor. [7]
BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI Patients BRILINTA Recognized Across Major US Treatment Guidelines for ...
The FDA accepts AstraZeneca's (AZN) sNDA for Brilinta under a Priority Review to lower subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.
For premium support please call: 800-290-4726 more ways to reach us more ways to reach us
[81] [82] Concerns regarding the long-term effects of benzodiazepines have been raised since 1980. [83] These concerns are still not fully answered. A review in 2006 of the literature on use of benzodiazepine and nonbenzodiazepine hypnotics concluded that more research is needed to evaluate the long-term effects of hypnotic drugs. [84]
Individuals who have had more withdrawal episodes are at an increased risk of very severe withdrawal symptoms, up to and including seizures and death. Long-term activation of the GABA receptor by sedative–hypnotic drugs causes chronic GABA receptor downregulation as well as glutamate overactivity, which can lead to drug and neurotransmitter ...
For premium support please call: 800-290-4726 more ways to reach us
Due to these contraindications and the possibility of it causing severe adverse effects including seizures, adverse cardiac effects, and death, [50] [51] in the majority of cases there is no indication for the use of flumazenil in the management of benzodiazepine overdose as the risks in general outweigh any potential benefit of administration.